Seems to me the FDA article is an extremely risky,
Post# of 148190
CD10 actually achieved "Clinical Signficance" for its Primary Endpoint, and "Statistical Significance" for the Secondary Endpoint NEWS2.
FDA today says....
In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints.